Roxindole hydrochloride | CAS# 108050-82-4 | Dopamine D2 autoreceptor agonist

MedKoo Cat#: 574390 | Name: Roxindole hydrochloride

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Roxindole hydrochloride is a dopamine D2 autoreceptor agonist with affinity for D3, D4 and 5-HT1 receptors. It inhibits 5-HT uptake and is antidepressant in vivo.

Chemical Structure

Roxindole hydrochloride

CAS#108050-82-4

Theoretical Analysis

MedKoo Cat#: 574390

Name: Roxindole hydrochloride

CAS#: 108050-82-4

Chemical Formula: C23H27ClN2O

Exact Mass: 382.1812

Molecular Weight: 382.93

Elemental Analysis: C, 72.14; H, 7.11; Cl, 9.26; N, 7.32; O, 4.18

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 450.00	2 Weeks
50mg	USD 1,250.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Roxindole hydrochloride, Roxindole HCl

IUPAC/Chemical Name

3-[4-(3,6-Dihydro-4-phenyl-1(2H)-pyridinyl)butyl]-1H-indol-5-ol hydrochloride

InChi Key

ZCEPVNSWLLJECX-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H26N2O.ClH/c26-21-9-10-23-22(16-21)20(17-24-23)8-4-5-13-25-14-11-19(12-15-25)18-6-2-1-3-7-18;/h1-3,6-7,9-11,16-17,24,26H,4-5,8,12-15H2;1H

SMILES Code

OC1=CC2=C(NC=C2CCCCN3CC=C(C4=CC=CC=C4)CC3)C=C1.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 382.93 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Maj J, Kolodziejczyk K, Rogóz Z, Skuza G. Roxindole, a potential antidepressant. I. Effect on the dopamine system. J Neural Transm (Vienna). 1996;103(5):627-41. doi: 10.1007/BF01273159. PMID: 8811507. 2: Bartoszyk GD, Harting J, Minck KO. Roxindole: psychopharmacological profile of a dopamine D2 autoreceptor agonist. J Pharmacol Exp Ther. 1996 Jan;276(1):41-8. PMID: 8558454. 3: Gründer G, Wetzel H, Hammes E, Benkert O. Roxindole, a dopamine autoreceptor agonist, in the treatment of major depression. Psychopharmacology (Berl). 1993;111(1):123-6. doi: 10.1007/BF02257418. PMID: 7870927. 4: Newman-Tancredi A, Cussac D, Audinot V, Millan MJ. Actions of roxindole at recombinant human dopamine D2, D3 and D4 and serotonin 5-HT1A, 5-HT1B and 5-HT1D receptors. Naunyn Schmiedebergs Arch Pharmacol. 1999 Jun;359(6):447-53. doi: 10.1007/pl00005374. PMID: 10431754. 5: Seyfried CA, Adam G. Studies on the interaction of roxindole with brain monoamine oxidases and dopaminergic neurones in vitro and in vivo. Pharmacol Toxicol. 1994 Jun;74(6):314-20. doi: 10.1111/j.1600-0773.1994.tb01366.x. PMID: 7937563. 6: Benkert O, Gründer G, Wetzel H. Dopamine autoreceptor agonists in the treatment of schizophrenia and major depression. Pharmacopsychiatry. 1992 Nov;25(6):254-60. doi: 10.1055/s-2007-1014417. PMID: 1362997. 7: Gründer G, Wetzel H, Hillert A, Jochum E, Hiemke C, Benkert O. The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. Psychopharmacology (Berl). 1995 Feb;117(4):472-8. doi: 10.1007/BF02246221. PMID: 7604150. 8: Wetzel H, Hillert A, Gründer G, Benkert O. Roxindole, a dopamine autoreceptor agonist, in the treatment of positive and negative schizophrenic symptoms. Am J Psychiatry. 1994 Oct;151(10):1499-502. doi: 10.1176/ajp.151.10.1499. PMID: 7916543. 9: Lange JH, de Jong JC, Sanders HJ, Visser GM, Kruse CG. A straightforward synthetic approach for roxindole. Bioorg Med Chem Lett. 1999 Apr 5;9(7):1055-6. doi: 10.1016/s0960-894x(99)00135-3. PMID: 10230639. 10: Wiedemann K, Kellner M. Endocrine characterization of the new dopamine autoreceptor agonist roxindole. Exp Clin Endocrinol. 1994;102(4):284-8. doi: 10.1055/s-0029-1211293. PMID: 7813599. 11: Maj J, Kołodziejczyk K, Rogóz Z, Skuza G. Roxindole, a dopamine autoreceptor agonist with a potential antidepressant activity. II. Effects on the 5-hydroxytryptamine system. Pharmacopsychiatry. 1997 Mar;30(2):55-61. doi: 10.1055/s-2007-979483. PMID: 9131725. 12: Seyfried CA, Bartoszyk GD. Sensitivity of dopamine D2 receptors following long-term treatment with roxindole. Eur J Pharmacol. 1994 May 12;257(1-2):67-72. doi: 10.1016/0014-2999(94)90695-5. PMID: 7915991. 13: Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997 Jul;12 Suppl 3:S7-14. doi: 10.1097/00004850-199707003-00002. PMID: 9347387. 14: Csende F. A simple procedure for synthesis of roxindole, a dopamine D2-receptor agonist. Arch Pharm (Weinheim). 2001 Jul;334(7):253-4. doi: 10.1002/1521-4184(200107)334:7<253::aid-ardp253>3.0.co;2-#. PMID: 11512277. 15: Ninan I, Kulkarni SK. Involvement of dopamine D2 and 5-HT1A receptors in roxindole-induced antinociception. Indian J Exp Biol. 1999 Mar;37(3):234-7. PMID: 10641151. 16: Kasper S, Fuger J, Zinner HJ, Bäuml J, Möller HJ. Early clinical results with the neuroleptic roxindole (EMD 49,980) in the treatment of schizophrenia-- an open study. Eur Neuropsychopharmacol. 1992 Mar;2(1):91-5. doi: 10.1016/0924-977x(92)90041-6. PMID: 1353388. 17: Benkert O, Müller-Siecheneder F, Wetzel H. Dopamine agonists in schizophrenia: a review. Eur Neuropsychopharmacol. 1995;5 Suppl:43-53. doi: 10.1016/0924-977x(95)00022-h. PMID: 8775758. 18: Filip M, Wydra K, Inan SY, Dziedzicka-Wasylewska M, Przegaliński E. Opioid and monoamine systems mediate the discriminative stimulus of tramadol in rats. Eur J Pharmacol. 2004 Sep 13;498(1-3):143-51. doi: 10.1016/j.ejphar.2004.07.090. PMID: 15363988. 19: Newman-Tancredi A, Cussac D, Quentric Y, Touzard M, Verrièle L, Carpentier N, Millan MJ. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes. J Pharmacol Exp Ther. 2002 Nov;303(2):815-22. doi: 10.1124/jpet.102.039883. PMID: 12388668. 20: Bartoszyk GD. Anxiolytic effects of dopamine receptor ligands: I. Involvement of dopamine autoreceptors. Life Sci. 1998;62(7):649-63. doi: 10.1016/s0024-3205(97)01160-0. PMID: 9472724.